{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T13:22:35Z","timestamp":1795094555019,"version":"4.10.2"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"19","license":[{"start":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000},"content-version":"vor","delay-in-days":104,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"N\/A"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Outcomes for patients with recurrent\/metastatic (R\/M) head and neck squamous cell carcinoma (HNSCC) are poor, with median overall survival (OS) ranging from 6 to 18 months. For those who progress on standard-of-care (chemo)immunotherapy, treatment options are limited, necessitating the development of rational therapeutic strategies. Toward this end, we targeted the key HNSCC drivers PI3K\u2013mTOR and HRAS via the combination of tipifarnib, a farnesyltransferase (FTase) inhibitor, and alpelisib, a PI3K\u03b1 inhibitor, in multiple molecularly defined subsets of HNSCC. Tipifarnib synergized with alpelisib at the level of mTOR in PI3K\u03b1- or HRAS-dependent HNSCCs, leading to marked cytotoxicity in vitro and tumor regression in vivo. On the basis of these findings, the KURRENT-HN trial was launched to evaluate the effectiveness of this combination in PIK3CA-mutant\/amplified and\/or HRAS-overexpressing R\/M HNSCC. Preliminary evidence supports the clinical activity of this molecular biomarker-driven combination therapy. Combined alpelisib and tipifarnib has potential to benefit &amp;gt;45% of patients with R\/M HNSCC. By blocking feedback reactivation of mTORC1, tipifarnib may prevent adaptive resistance to additional targeted therapies, enhancing their clinical utility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>The mechanistically designed, biomarker-matched strategy of combining alpelisib and tipifarnib is efficacious in PIK3CA- and HRAS-dysregulated head and neck squamous carcinoma and could improve outcomes for many patients with recurrent, metastatic disease.<\/jats:p>\n                    <jats:p>See related commentary by Lee et al., p. 3162<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-23-0282","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T13:56:25Z","timestamp":1687269385000},"page":"3252-3263","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Tipifarnib Potentiates the Antitumor Effects of PI3K\u03b1 Inhibition in\n                    <i>PIK3CA<\/i>\n                    - and\n                    <i>HRAS<\/i>\n                    -Dysregulated HNSCC via Convergent Inhibition of mTOR Activity"],"prefix":"10.1158","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2385-1011","authenticated-orcid":false,"given":"Alison E.","family":"Smith","sequence":"first","affiliation":[{"name":"1Kura Oncology, Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6690-0929","authenticated-orcid":false,"given":"Stacia","family":"Chan","sequence":"additional","affiliation":[{"name":"1Kura Oncology, Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3574-6078","authenticated-orcid":false,"given":"Zhiyong","family":"Wang","sequence":"additional","affiliation":[{"name":"2Moores Cancer Center, University of California San Diego, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7606-187X","authenticated-orcid":false,"given":"Asako","family":"McCloskey","sequence":"additional","affiliation":[{"name":"1Kura Oncology, Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8725-8232","authenticated-orcid":false,"given":"Quinn","family":"Reilly","sequence":"additional","affiliation":[{"name":"1Kura Oncology, Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5669-3933","authenticated-orcid":false,"given":"Jayden Z.","family":"Wang","sequence":"additional","affiliation":[{"name":"1Kura Oncology, Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0647-7446","authenticated-orcid":false,"given":"Hetika Vora","family":"Patel","sequence":"additional","affiliation":[{"name":"1Kura Oncology, Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0431-8337","authenticated-orcid":false,"given":"Keiichi","family":"Koshizuka","sequence":"additional","affiliation":[{"name":"2Moores Cancer Center, University of California San Diego, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4351-1363","authenticated-orcid":false,"given":"Harris S.","family":"Soifer","sequence":"additional","affiliation":[{"name":"1Kura Oncology, Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8677-3252","authenticated-orcid":false,"given":"Linda","family":"Kessler","sequence":"additional","affiliation":[{"name":"1Kura Oncology, Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1206-679X","authenticated-orcid":false,"given":"Ashley","family":"Dayoub","sequence":"additional","affiliation":[{"name":"3Kura Oncology, Inc., Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9111-1034","authenticated-orcid":false,"given":"Victoria","family":"Villaflor","sequence":"additional","affiliation":[{"name":"4City of Hope Comprehensive Cancer Center, Duarte, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3207-8227","authenticated-orcid":false,"given":"Douglas R.","family":"Adkins","sequence":"additional","affiliation":[{"name":"5Washington University at St. Louis, St. Louis, Missouri."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5902-7430","authenticated-orcid":false,"given":"Justine Y.","family":"Bruce","sequence":"additional","affiliation":[{"name":"6Wisconsin University, Madison, Wisconsin."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6885-3742","authenticated-orcid":false,"given":"Alan L.","family":"Ho","sequence":"additional","affiliation":[{"name":"7Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5860-4921","authenticated-orcid":false,"given":"Cesar A.","family":"Perez","sequence":"additional","affiliation":[{"name":"8Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9969-2523","authenticated-orcid":false,"given":"Glenn J.","family":"Hanna","sequence":"additional","affiliation":[{"name":"9Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2838-9076","authenticated-orcid":false,"given":"Amaya","family":"Gasc\u00f3 Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"3Kura Oncology, Inc., Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4510-6048","authenticated-orcid":false,"given":"Andrew","family":"Saunders","sequence":"additional","affiliation":[{"name":"3Kura Oncology, Inc., Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1113-7136","authenticated-orcid":false,"given":"Stephen","family":"Dale","sequence":"additional","affiliation":[{"name":"3Kura Oncology, Inc., Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5150-4482","authenticated-orcid":false,"given":"J. Silvio","family":"Gutkind","sequence":"additional","affiliation":[{"name":"2Moores Cancer Center, University of California San Diego, La Jolla, California."},{"name":"10Department of Pharmacology, University of California San Diego, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0274-4911","authenticated-orcid":false,"given":"Francis","family":"Burrows","sequence":"additional","affiliation":[{"name":"1Kura Oncology, Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2681-7646","authenticated-orcid":false,"given":"Shivani","family":"Malik","sequence":"additional","affiliation":[{"name":"1Kura Oncology, Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2023,6,20]]},"reference":[{"key":"2025112418074833400_bib1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2025112418074833400_bib2","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.3390\/cancers13102371","article-title":"Recurrent\/metastatic squamous cell carcinoma of the head and neck: a big and intriguing challenge which may be resolved by integrated treatments combining locoregional and systemic therapies","volume":"13","author":"Ionna","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025112418074833400_bib3","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet North Am Ed"},{"key":"2025112418074833400_bib4","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1158\/2159-8290.CD-13-0103","article-title":"Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers","volume":"3","author":"Lui","year":"2013","journal-title":"Cancer Discov"},{"key":"2025112418074833400_bib5","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nature14129","article-title":"Comprehensive genomic characterization of head and neck squamous cell carcinomas","volume":"517","year":"2015","journal-title":"Nature"},{"key":"2025112418074833400_bib6","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1200\/JCO.2017.72.7107","article-title":"Phosphatidylinositol 3-Kinase \u03b1-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study","volume":"36","author":"Juric","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025112418074833400_bib7","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ccr.2010.10.031","article-title":"AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity","volume":"19","author":"Chandarlapaty","year":"2011","journal-title":"Cancer Cell"},{"key":"2025112418074833400_bib8","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O'Reilly","year":"2006","journal-title":"Cancer Res"},{"key":"2025112418074833400_bib9","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1210\/mend.14.6.0446","article-title":"A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1","volume":"14","author":"Haruta","year":"2000","journal-title":"Mol Endocrinol"},{"key":"2025112418074833400_bib10","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ccell.2015.03.010","article-title":"AXL mediates resistance to PI3K\u03b1 inhibition by activating the EGFR\/PKC\/mTOR axis in head and neck and esophageal squamous cell carcinomas","volume":"27","author":"Elkabets","year":"2015","journal-title":"Cancer Cell"},{"key":"2025112418074833400_bib11","first-page":"3065","article-title":"Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer","volume":"118","author":"Carracedo","year":"2008","journal-title":"J Clin Invest"},{"key":"2025112418074833400_bib12","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1126\/science.1199484","article-title":"Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling","volume":"332","author":"Yu","year":"2011","journal-title":"Science"},{"key":"2025112418074833400_bib13","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1038\/onc.2010.626","article-title":"PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer","volume":"30","author":"Serra","year":"2011","journal-title":"Oncogene"},{"key":"2025112418074833400_bib14","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.ijrobp.2019.09.050","article-title":"A phase 1b study of cetuximab and BYL719 (Alpelisib) concurrent with intensity modulated radiation therapy in stage III-IVB head and neck squamous cell carcinoma","volume":"106","author":"Dunn","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025112418074833400_bib15","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.bbrc.2006.03.220","article-title":"Localization of Rheb to the endomembrane is critical for its signaling function","volume":"344","author":"Buerger","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"2025112418074833400_bib16","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41557-019-0237-6","article-title":"Dual chemical probes enable quantitative system-wide analysis of protein prenylation and prenylation dynamics","volume":"11","author":"Storck","year":"2019","journal-title":"Nat Chem"},{"key":"2025112418074833400_bib17","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1242\/jcs.182873","article-title":"RAS isoforms and mutations in cancer at a glance","volume":"129","author":"Hobbs","year":"2016","journal-title":"J Cell Sci"},{"key":"2025112418074833400_bib18","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.molcel.2012.05.007","article-title":"Cooperative Activation of PI3K by Ras and Rho Family Small GTPases","volume":"47","author":"Yang Hee","year":"2012","journal-title":"Mol Cell"},{"key":"2025112418074833400_bib19","doi-asserted-by":"crossref","first-page":"24052","DOI":"10.1074\/jbc.273.37.24052","article-title":"Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-Kinase","volume":"273","author":"Yan","year":"1998","journal-title":"J Biol Chem"},{"key":"2025112418074833400_bib20","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.cub.2005.02.053","article-title":"Rheb binds and regulates the mTOR kinase","volume":"15","author":"Long","year":"2005","journal-title":"Curr Biol"},{"key":"2025112418074833400_bib21","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1158\/0008-5472.CAN-18-1220","article-title":"4E-BP1 is a tumor suppressor protein reactivated by mTOR inhibition in head and neck cancer","volume":"79","author":"Wang","year":"2019","journal-title":"Cancer Res"},{"key":"2025112418074833400_bib22","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.oraloncology.2018.07.010","article-title":"ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition","volume":"84","author":"Ruicci","year":"2018","journal-title":"Oral Oncol"},{"key":"2025112418074833400_bib23","doi-asserted-by":"crossref","first-page":"31892","DOI":"10.18632\/oncotarget.7441","article-title":"A positive feedback loop involving EGFR\/Akt\/mTORC1 and IKK\/NF-kB regulates head and neck squamous cell carcinoma proliferation","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"2025112418074833400_bib24","doi-asserted-by":"crossref","first-page":"196ra99","DOI":"10.1126\/scitranslmed.3005747","article-title":"mTORC1 inhibition is required for sensitivity to PI3K p110\u03b1 inhibitors in PIK3CA-mutant breast cancer","volume":"5","author":"Elkabets","year":"2013","journal-title":"Sci Transl Med"},{"key":"2025112418074833400_bib25","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ccell.2016.06.004","article-title":"PDK1-SGK1 signaling sustains AKT-independent mTORC1 activation and confers resistance to PI3K\u03b1 inhibition","volume":"30","author":"Castel","year":"2016","journal-title":"Cancer Cell"},{"key":"2025112418074833400_bib26","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1158\/1535-7163.MCT-19-0958","article-title":"Tipifarnib as a precision therapy for HRAS-mutant head and neck squamous cell carcinomas","volume":"19","author":"Gilardi","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"2025112418074833400_bib27","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1200\/JCO.20.02903","article-title":"Tipifarnib in head and neck squamous cell carcinoma with HRAS mutations","volume":"39","author":"Ho","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025112418074833400_bib28","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"2025112418074833400_bib29","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1038\/s41467-021-22619-w","article-title":"Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer","volume":"12","author":"Wang","year":"2021","journal-title":"Nat Commun"},{"key":"2025112418074833400_bib30","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.cell.2007.03.051","article-title":"Binding of Ras to phosphoinositide 3-Kinase p110\u03b1 is required for Ras- driven tumorigenesis in mice","volume":"129","author":"Gupta","year":"2007","journal-title":"Cell"},{"key":"2025112418074833400_bib31","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1073\/pnas.0712169105","article-title":"Helical domain and kinase domain mutations in p110\u03b1 of phosphatidylinositol 3-kinase induce gain of function by different mechanisms","volume":"105","author":"Zhao","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025112418074833400_bib32","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.3390\/cancers13215310","article-title":"Potential of farnesyl transferase inhibitors in combination regimens in squamous cell carcinomas","volume":"13","author":"Kessler","year":"2021","journal-title":"Cancers"},{"key":"2025112418074833400_bib33","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1158\/1078-0432.CCR-20-3652","article-title":"FDA approval summary: alpelisib plus fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer","volume":"27","author":"Narayan","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025112418074833400_bib34","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1172\/JCI41680","article-title":"Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer","volume":"120","author":"Miller","year":"2010","journal-title":"J Clin Invest"},{"key":"2025112418074833400_bib35","doi-asserted-by":"crossref","first-page":"283ra51","DOI":"10.1126\/scitranslmed.aaa4442","article-title":"PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor\u2013positive breast cancer","volume":"7","author":"Bosch","year":"2015","journal-title":"Sci Transl Med"},{"key":"2025112418074833400_bib36","doi-asserted-by":"crossref","first-page":"R40","DOI":"10.1186\/bcr2594","article-title":"Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer","volume":"12","author":"Creighton","year":"2010","journal-title":"Breast Cancer Res"},{"key":"2025112418074833400_bib37","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1634\/theoncologist.2016-0145","article-title":"A phase Ib study of BEZ235, a dual inhibitor of phosphatidylinositol 3-Kinase (PI3K) and mammalian target of rapamycin (mTOR), in patients with advanced renal cell carcinoma","volume":"21","author":"Carlo","year":"2016","journal-title":"Oncologist"},{"key":"2025112418074833400_bib38","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.3390\/ijms21031060","article-title":"Is there a role for dual PI3K\/mTOR inhibitors for patients affected with lymphoma?","volume":"21","author":"Tarantelli","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025112418074833400_bib39","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejca.2021.03.042","article-title":"Alpelisib in combination with everolimus \u00b1 exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study","volume":"151","author":"Curigliano","year":"2021","journal-title":"Eur J Cancer"},{"key":"2025112418074833400_bib40","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","article-title":"Targeting the PI3K pathway in cancer: are we making headway?","volume":"15","author":"Janku","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2025112418074833400_bib41","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1158\/1078-0432.CCR-11-2381","article-title":"The clinical effect of the dual-targeting strategy involving PI3K\/AKT\/mTOR and RAS\/MEK\/ERK pathways in patients with advanced cancer","volume":"18","author":"Shimizu","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2025112418074833400_bib42","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1126\/science.1215135","article-title":"Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity","volume":"335","author":"Lamming","year":"2012","journal-title":"Science"},{"key":"2025112418074833400_bib43","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11523-011-0174-9","article-title":"Common toxicities of mammalian target of rapamycin inhibitors","volume":"6","author":"Soefje","year":"2011","journal-title":"Targeted Oncology"},{"key":"2025112418074833400_bib44","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.chembiol.2022.02.006","article-title":"Rheb regulates nuclear mTORC1 activity independent of farnesylation","volume":"29","author":"Zhong","year":"2022","journal-title":"Cell Chem Biol"},{"key":"2025112418074833400_bib45","doi-asserted-by":"crossref","first-page":"31101","DOI":"10.1074\/jbc.M503763200","article-title":"The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits rheb farnesylation and mTOR signaling: role in FTI enhancement of taxane and tamoxifen anti-tumor activity","volume":"280","author":"Basso","year":"2005","journal-title":"J Biol Chem"},{"key":"2025112418074833400_bib46","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1101\/gad.1690808","article-title":"Tumorigenic activity and therapeutic inhibition of Rheb GTPase","volume":"22","author":"Mavrakis","year":"2008","journal-title":"Genes Dev"},{"key":"2025112418074833400_bib47","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3324\/haematol.2013.087734","article-title":"Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells","volume":"99","author":"Ding","year":"2014","journal-title":"Haematologica"},{"key":"2025112418074833400_bib48","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1101\/gad.1699608","article-title":"Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events","volume":"22","author":"Nardella","year":"2008","journal-title":"Genes Dev"},{"key":"2025112418074833400_bib49","doi-asserted-by":"crossref","first-page":"196ra98","DOI":"10.1126\/scitranslmed.3005753","article-title":"TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma","volume":"5","author":"Corcoran","year":"2013","journal-title":"Sci Transl Med"},{"key":"2025112418074833400_bib50","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discov"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-23-0282\/3344287\/can-23-0282.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/83\/19\/3252\/3367124\/3252.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/83\/19\/3252\/3367124\/3252.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T23:08:03Z","timestamp":1764025683000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/83\/19\/3252\/729238\/Tipifarnib-Potentiates-the-Antitumor-Effects-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,20]]},"references-count":50,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2023,6,20]]},"published-print":{"date-parts":[[2023,10,2]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-23-0282","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.24228937.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27028354.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30701209","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27028354","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27028357.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27028357","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.24228937","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6861202","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6861202.v3","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6861202.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6861202.v2","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,20]]}}}